KPKarl S. Peggs

Karl S. Peggs

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Karl S. Peggs has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Chen Qing

    University College London 1 Immune Regulation and Tumor Immunotherapy Group, Cancer Immunology Unit, Research Department of Hematology, Cancer Institute London, United Kingdom

    1 shared publication
  • Cristobal Costoya

    University College London 1 Immune Regulation and Tumor Immunotherapy Group, Cancer Immunology Unit, Research Department of Hematology, Cancer Institute London, United Kingdom

    1 shared publication
  • Ehsan Ghorani

    Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK

    1 shared publication
  • Felipe Galvez-Cancino

    University of Oxford 1 Laboratory of Immune-Regulation, NDM Centre for Immuno-Oncology Oxford, United Kingdom

    1 shared publication
  • Gordon Beattie

    University College London 4 Genomics Translational Technology Platform, UCL Cancer Institute London, United Kingdom

    1 shared publication
  • Henning Walczak

    Cell Death, Inflammation and Immunity Laboratory, CECAD Research Center and Institute of Biochemistry I (IBC1) of the Faculty of Medicine, University of Cologne, Cologne, Germany

    1 shared publication

Latest Publications

  • FasL-Mediated Death of Activated Intratumoral T Cells Drives Secondary Resistance to Cancer Immunotherapy

    by Chen Qing, Ehsan Ghorani, Kane A. Foster, Imran Uddin, Gordon Beattie, Cristobal Costoya, Felipe Galvez-Cancino, Henning Walczak, Maria Amann, Karl S. Peggs, et al.

    Cancer progression following an initial response to immunotherapy [secondary resistance (2°R)] is a major and poorly understood problem. We treated mice bearing B16 melanoma with a combination of a regulatory T cell (Treg)–depleting, non–IL2-blocking anti-CD25 (anti-CD25NIB) antibody and an autologous cancer cell vaccine (GVAX). The regimen yielded initial tumor shrinkage followed by 2°R; lethal progression occurred in ∼90% of partially responsive (PR) tumors by days 35 to 50. Cell lines derived from 2°R tumors retained treatment sensitivity upon reimplantation into naïve mice, suggesting that resistance was related to a loss of immune control over time. Profiling PR and 2°R tumors by flow cytometry and single-cell RNA/T-cell receptor (TCR) sequencing, we found that activated CD8+ T cells with tumor-reactive features declined in abundance, whereas nonactivated T cells and Tregs increased. Activated CD8+ cells showed heightened TCR stimulation, clonal expansion, and expression of apoptotic signatures and death receptors, including Fas. Their loss was not explained by lymph node accumulation or differentiation to nonactivated states. These findings were validated in a clinically relevant MC38 colon carcinoma model treated with anti–PD-L1 checkpoint blockade, confirming that depletion of activated, tumor-reactive clones is a shared mechanism of 2°R across therapeutic modalities. Fas ligand (FasL) blockade reversed this loss and prolonged survival. Longitudinal transcriptional and tissue staining data from human checkpoint blockade studies similarly indicated that activated T cells decline in abundance over time and at 2°R. These findings implicate death of activated T cells as a mechanism of 2°R and suggest that Fas–FasL blockade may extend response durability.